Epidermal growth factor (EGF) is a small protein your body naturally produces to signal cells to grow, divide, and repair. It plays a central role in wound healing, skin renewal, and tissue maintenance. Found in saliva, breast milk, blood, and other body fluids, EGF works by docking onto a specific receptor on cell surfaces, triggering a cascade of signals that tell the cell to multiply or mature. This protein has become important in two very different worlds: cancer treatment and skincare.
What EGF Does in Your Body
EGF is a tiny protein, only about 6,200 daltons in molecular weight, making it one of the smaller signaling molecules your body uses. Its primary job is stimulating the growth and division of epithelial cells, the type that line your skin, gut, and organs. When EGF binds to its receptor (called EGFR) on a cell’s surface, it kicks off a chain reaction inside the cell that ramps up the production of DNA, RNA, and new proteins. The result is faster cell turnover and tissue repair.
Your body produces EGF in surprisingly varied locations. Measurements of human body fluids show the highest concentrations in urine (about 80 ng/ml) and breast milk (65 ng/ml), followed by seminal plasma (50 ng/ml) and sweat from the underarms (25 ng/ml). Saliva contains around 3 ng/ml, and tears about 1.5 ng/ml. Even gastric juice contains trace amounts. This wide distribution reflects how many tissues rely on EGF for routine maintenance and repair.
Beyond just telling cells to divide, EGF also promotes cell migration. When you get a cut, EGF helps draw epithelial cells toward the wound site so they can cover the exposed area. This dual action, proliferation plus migration, is why EGF is so central to healing.
How EGF Was Discovered
American biochemist Stanley Cohen stumbled onto EGF while studying a completely different protein, nerve growth factor, in the 1960s. He was injecting salivary gland extracts into newborn mice and noticed something unexpected: their eyelids opened earlier than normal and their teeth came in ahead of schedule. The salivary extract contained a second growth factor that was accelerating skin and epithelial development. Cohen isolated this substance, determined its amino acid sequence, and named it epidermal growth factor. The work earned him the 1986 Nobel Prize in Physiology or Medicine, shared with Rita Levi-Montalcini for her discovery of nerve growth factor.
The EGF Receptor and Cancer
The same signaling system that makes EGF useful for healing also makes it dangerous when it malfunctions. The EGF receptor, EGFR, is one of the most commonly overproduced or mutated proteins in cancer. When cells make too many copies of EGFR, or when the receptor becomes permanently stuck in the “on” position, cells divide uncontrollably.
EGFR overproduction is especially common in brain tumors (glioblastoma), lung cancer, colorectal cancer, and breast cancer. In glioblastoma, a mutated version called EGFRvIII, which has a large chunk of its normal structure deleted, is the most frequent genetic abnormality. In lung cancer, the mutations tend to be smaller, often single-point changes in the part of the receptor that processes energy signals.
This understanding has led to an entire class of cancer drugs that block EGFR. These fall into two categories: small-molecule drugs that slip inside the cell and block the receptor’s internal signaling machinery, and antibody drugs that latch onto the receptor’s outer surface and prevent EGF from binding. Approved drugs in the first category target lung cancer and, in some cases, pancreatic cancer. The antibody drugs are used primarily for colorectal cancer and head and neck cancers. Three generations of these drugs now exist, each designed to overcome resistance that tumors develop to earlier versions.
EGF in Wound Healing
Synthetic versions of EGF, called recombinant human EGF (rhEGF), are used medically to treat chronic wounds that resist normal healing. The best-studied application is diabetic foot ulcers, a common and serious complication of diabetes where reduced blood flow and nerve damage slow the body’s natural repair processes.
A meta-analysis of nine randomized controlled trials covering 720 patients found that rhEGF nearly tripled the odds of complete wound healing compared to placebo. Wounds treated with rhEGF also closed about two weeks faster on average. Topical application (gels or creams applied directly to the wound) worked better than injecting EGF into the wound edges. In individual trials, complete healing rates with topical EGF ranged from about 73% to 92%, compared to 44% to 67% with standard wound care alone. No significant increase in side effects was observed.
EGF in Skincare Products
The skincare industry has adopted EGF as an anti-aging ingredient, marketing it as a way to boost collagen production, reduce wrinkles, and improve skin texture. Clinical serums typically contain EGF at concentrations around 75 parts per million. Most commercial EGF is produced through bioengineering, using bacteria or yeast to manufacture the protein, though some newer formulations derive it from plants like barley. Plant-derived proteins can offer better stability during storage and transport, but the functional differences for skincare remain unclear.
The clinical evidence for cosmetic EGF is more modest than the marketing suggests. A systematic review of studies on topical growth factor preparations found a median improvement in wrinkle scores of about 34% after three months of use. Improvements in overall facial appearance were smaller, with a median under 20%. Skin texture showed moderate gains, with most studies reporting less than 50% improvement. These are real but incremental changes, not the dramatic transformations some brands promise.
Safety Considerations
The biggest open question about topical EGF is whether applying a growth-promoting protein to skin could encourage cancer. Because EGFR overactivity drives several cancers, this concern is not trivial. Some preclinical studies have found that externally applied EGF does not stimulate tumor growth in animal models, but other research has shown the opposite. The evidence is currently insufficient for clear consensus guidelines.
In clinical use for wound healing and radiation-related skin damage, topical EGF has been well tolerated with no severe adverse effects. For cosmetic use on healthy skin, no long-term safety studies have raised red flags, but the research base is thinner. People with a history of skin cancer or precancerous lesions have the most reason to be cautious, since adding growth signals to cells that are already prone to abnormal division is, at minimum, a theoretical risk that hasn’t been fully resolved.